Following #CTOS25, @danafarbernews.bsky.social’s Suzanne George, MD, discussed with CURE the ongoing phase 1/2 DCC-3009 study in advanced gastrointestinal stromal tumor (GIST) for patients whose disease has progressed on multiple prior targeted therapies.
Read more: bit.ly/498sMbI
Building Global Sarcoma Connections at CTOS 2025 - Herbert Loong
@herbloongmd.bsky.social
oncodaily.com/voices/409198
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CTOS #CTOS25 #CTOS2025
Waterfall plot of response rate with lete-cell in SS/MRCLS with 43% ORR
Paired waterfall plot and KM curves of afami-cel and lete-cel
More data on TCRs in synovial sarcoma/MRCLS! In pooled analysis, Lete-cel (NY-ESO-1), w/ similar ORR to afami-cel (MAGEA4) & median OS 20.5 mo w/ small subset long-term responders.
Exciting to have multiple cell therapy options, need further studies to know how to seq & cross-sensitivity. #CTOS25
A man stands at a podium in front of a slide, the top of which reads "Conclusions: there are many ways to lose your shirt"
Wisdom from #JCO assoc editor Bob Maki at #CTOS25:
“There are many ways to lose your shirt. Las Vegas, Crypto, and [bad] statistical design.”
Dana-Farber Cancer Institute at #CTOS25
Dana-Farber Cancer Institute at #CTOS25
Heading to #CTOS25? Check out this list of @danafarber.bsky.social research presentations, panels, and posters that will be presented at the conference in Boca Raton, FL from Nov. 12-15.
